23andMe Launches New Genetic Report on Bipolar Disorder
23andMe Launches New Genetic Report on Bipolar Disorder
Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variants
爲23andMe+ 高級會員提供基於數千種遺傳變異的深入了解他們患上嚴重心理健康疾病的可能性
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition. Bipolar disorder is a mental health condition that can cause extreme and unusual shifts in mood, energy, behavior and activity, ranging from highs (mania) to lows (depression).
加利福尼亞州南舊金山,2024 年 6 月 5 日(GLOBE NEWSWIRE)— 23andMe Holding Co.納斯達克股票代碼:ME)是一家領先的人類遺傳學和生物製藥公司,今天爲23andMe+高級會員發佈了一份新的遺傳雙相情感障礙報告(由23andMe Research提供支持),告知他們被診斷出患有這種疾病的可能性是否更高。躁鬱症是一種心理健康狀況,可導致情緒、精力、行爲和活動發生極端和異常的變化,從高潮(躁狂)到低潮(抑鬱)不等。
According to the National Institute of Mental Health, 4.4 percent of American adults have experienced bipolar disorder at some point in their lives, meaning approximately 14 million people in the US have bipolar disorder – about 1 in 100 individuals. Genetics play a major role in bipolar disorder, which is estimated to be between 44-90% heritable.
根據 國立心理健康研究所,4.4%的美國成年人在生命中的某個時刻經歷過躁鬱症,這意味着美國約有1400萬人患有躁鬱症,大約每100人中就有1人。遺傳學在躁鬱症中起着重要作用,即 估計可遺傳率在 44-90% 之間。
23andMe's new report is based on a statistical model known as polygenic risk score (PRS), developed by 23andMe through its proprietary research database. The Bipolar Disorder PRS report calculates the likelihood of an individual being diagnosed with the condition based on thousands of different genetic variants, as well as a customer's genetic ancestry and birth sex. This report follows other mental health PRS reports that 23andMe has made available to its 23andMe+ Premium members, including reports for Anxiety, Panic Attacks, and Depression.
23andMe的新報告基於一種名爲多基因風險評分(PRS)的統計模型,該模型由23andMe通過其專有研究數據庫開發。躁鬱症PRS報告根據數千種不同的遺傳變異以及客戶的遺傳血統和出生性別,計算出一個人被診斷出患有這種疾病的可能性。本報告是在23andMe向其23andMe+ Premium會員提供的其他心理健康PRS報告之後發佈的,包括焦慮、驚恐發作和抑鬱症的報告。
"According to the CDC, more than one in five adults live with mental illness. Knowing a person's genetic likelihood for developing bipolar disorder can help identify potential symptoms early on," said Noura Abul-Husn, MD, PhD, Vice President of Genomic Health at 23andMe. "While there is still ongoing research to understand the causes of bipolar disorder, there are effective treatments and strategies to help manage symptoms. We hope this report, and our other mental health PRS reports, can help reduce some of the stigma around these conditions by providing another resource for people seeking new ways to take care of their well-being."
“根據疾病預防控制中心的數據,超過五分之一的成年人患有精神疾病。了解一個人患雙相情感障礙的遺傳可能性有助於儘早發現潛在症狀。” 23andMe基因組健康副總裁努拉·阿布·胡斯醫學博士、博士說。“儘管仍在進行研究以了解躁鬱症的病因,但有有效的治療方法和策略可以幫助控制症狀。我們希望這份報告以及我們的其他心理健康PRS報告能夠爲尋求新的健康護理方式的人們提供另一種資源,從而幫助減少圍繞這些疾病的污名化。”
The Bipolar Disorder report was developed by 23andMe scientists and clinical experts using 23andMe's large database of genetic and health information contributed by consented research participants. This white paper provides full details on the science and methodology behind the Company's PRS technology.
躁鬱症報告由23andMe的科學家和臨床專家使用23andMe的大型遺傳和健康信息數據庫編寫,該數據庫由經同意的研究參與者提供。這個 白皮書 提供了有關公司 PRS 技術背後的科學和方法的完整詳細信息。
While genetic factors play a role, they do not determine whether a person will develop bipolar disorder. Other non-genetic factors—such as stressful life experiences—may also have an influence. To learn more about the new 23andMe Bipolar Disorder report and how to become a 23andMe+ Premium member, visit https://www.23andme.com/membership/.
儘管遺傳因素起着作用,但它們並不能決定一個人是否會患上躁鬱症。其他非遺傳因素,例如緊張的生活經歷,也可能會產生影響。要了解有關新的 23andMe 躁鬱症報告以及如何成爲 23andMe+ 高級會員的更多信息,請訪問 https://www.23andme.com/membership/。
About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit investors.23andme.com.
關於 23andMe
23andMe 是一家以基因爲主導的消費者醫療保健和治療公司,致力於打造更健康的未來。欲了解更多信息,請訪問 investors.23andme.com。
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "predicts," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
前瞻性陳述
本新聞稿包含經修訂的1933年《證券法》第27A條和經修訂的1934年《證券交易法》第21E條所指的前瞻性陳述,包括。除歷史事實陳述外,本新聞稿中包含或納入的所有陳述均爲前瞻性陳述。“相信”、“預期”、“估計”、“計劃”、“預期”、“打算”、“可能”、“應該”、“潛在”、“可能”、“項目”、“預測”、“繼續”、“將”、“計劃” 和 “將”,或者,在每種情況下,它們的負面或其他變體或可比術語旨在識別前瞻性陳述,儘管不是所有前瞻性陳述都包含這些識別詞。這些前瞻性陳述是基於23andMe當前對未來事件的預期和預測以及各種假設的預測。23andMe無法保證它會真正實現其前瞻性陳述中披露的計劃、意圖或預期,您不應過分依賴23andMe的前瞻性陳述。這些前瞻性陳述涉及許多風險、不確定性(其中許多是23andMe無法控制的)或其他假設,這些假設可能導致實際業績或業績與這些前瞻性陳述所表達或暗示的業績存在重大差異。此處包含的前瞻性陳述通常還受公司向美國證券交易委員會提交的文件中不時描述的其他風險和不確定性的影響,包括1A項下的公司向美國證券交易委員會提交的最新10-K表年度報告中的 “風險因素”,以及我們的10-Q表季度報告和8-K表最新報告的修訂和更新。此處發表的聲明是截至本新聞稿發佈之日發表的,除非法律要求,否則23andMe沒有義務對其進行更新,無論是由於新信息、事態發展還是其他原因。
Contact Information
press@23andme.com
investors@23andme.com